High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G

This publication has 37 references indexed in Scilit:

• The Role of New Agents in the Treatment of Colorectal Cancer
  Oncology, 2004
• Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
  Cancer, 2003
• Alemtuzumab
  Drugs, 2003
• Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma
  British Journal of Haematology, 2002
• Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin
  Japanese Journal of Cancer Research, 2002
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
  Blood, 2002
• Ig-binding Receptors on Human NK Cells as Effector and Regulatory Surface Molecules
  International Reviews of Immunology, 2001
• Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications
  Immunology Today, 1993
• Inhibition of lymphocyte and monocyte antibody-dependent cellular cytotoxicity by immune complexes: effect of normal human serum
  Immunology Letters, 1987
• The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
  International Journal of Cancer, 1986